Oruka Therapeutics (ORKA) Common Equity (2010 - 2026)

Oruka Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $486.7 million for Q1 2026.

• On a quarterly basis, Common Equity rose 33.45% year-over-year to $486.7 million in Q1 2026; TTM through Mar 2026 was $486.7 million, a 33.45% increase from a year earlier, with the FY2025 full-year figure at $471.9 million, up 23.47% from the prior year.
• Common Equity grew to $486.7 million in Q1 2026 per ORKA's latest filing, from $471.9 million in the prior quarter.
• Across five years, Common Equity topped out at $486.8 million in Q3 2025 and bottomed at -$29.0 million in Q2 2024.
• The 5-year median for Common Equity is $45.0 million (2022), against an average of $186.7 million.
• Across the five-year window, Common Equity plunged 173.86% in 2024 and soared 5266.81% in 2025, its largest moves.
• Year by year, Common Equity stood at $41.7 million in 2022, then retreated by 11.17% to $37.0 million in 2023, then soared by 932.47% to $382.2 million in 2024, then climbed by 23.47% to $471.9 million in 2025, then gained by 3.13% to $486.7 million in 2026.
• Per Business Quant, the three latest ORKA Common Equity figures stand at $486.7 million (Q1 2026), $471.9 million (Q4 2025), and $486.8 million (Q3 2025).